These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles. Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951 [TBL] [Abstract][Full Text] [Related]
4. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease]. Chen W; Man N; Li YS; Shan ZY; Teng WP Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113 [TBL] [Abstract][Full Text] [Related]
5. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Maugendre D; Massart C Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931 [TBL] [Abstract][Full Text] [Related]
6. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965 [TBL] [Abstract][Full Text] [Related]
7. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255 [TBL] [Abstract][Full Text] [Related]
8. Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment. Cho BY; Shong YK; Chung JK; Lee MC; Lee HK; Koh CS; Min HK Korean J Intern Med; 1990 Jan; 5(1):51-7. PubMed ID: 1980206 [TBL] [Abstract][Full Text] [Related]
9. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis. Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550 [TBL] [Abstract][Full Text] [Related]
10. Relationship between thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins years after administration of radioiodine for Graves' disease: retrospective clinical survey. Yoshida K; Aizawa Y; Kaise N; Fukazawa H; Kiso Y; Sayama N; Mori K; Hori H; Abe K J Endocrinol Invest; 1996 Nov; 19(10):682-6. PubMed ID: 9007700 [TBL] [Abstract][Full Text] [Related]
11. Effect of radioiodine on stimulatory activity of Graves' immunoglobulins. Atkinson S; McGregor AM; Kendall-Taylor P; Peterson MM; Smith BR Clin Endocrinol (Oxf); 1982 Jun; 16(6):537-43. PubMed ID: 6125279 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies. Kim WB; Chung HK; Park YJ; Park DJ; Lee HK; Cho BY Korean J Intern Med; 2001 Sep; 16(3):187-200. PubMed ID: 11769578 [TBL] [Abstract][Full Text] [Related]
13. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects. Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248 [TBL] [Abstract][Full Text] [Related]
14. Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment. Cho BY; Shong YK; Chung JK; Lee MC; Lee HK; Koh CS; Min HK Thyroidology; 1989 Dec; 1(3):109-14. PubMed ID: 2484872 [TBL] [Abstract][Full Text] [Related]
15. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease. Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336 [TBL] [Abstract][Full Text] [Related]
16. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease. Shibayama K; Ohyama Y; Yokota Y; Ohtsu S; Takubo N; Matsuura N Endocr J; 2005 Oct; 52(5):505-10. PubMed ID: 16284425 [TBL] [Abstract][Full Text] [Related]
17. Demonstration of anti-TSH antibody in TSH binding inhibitory immunoglobulin-positive sera of patients with Graves' disease. Ochi Y; Hamazu M; Kajita Y; Nagata A Clin Endocrinol (Oxf); 2002 Mar; 56(3):405-12. PubMed ID: 11940054 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease. Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017 [TBL] [Abstract][Full Text] [Related]
19. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease. Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459 [TBL] [Abstract][Full Text] [Related]
20. Simultaneous assay for three types of thyrotropin receptor antibody activities using FRTL-5 cells in patients with autoimmune thyroid diseases. Zhu Y; Portmann L; Dénéréaz N; Lemarchand-Béraud T Eur J Endocrinol; 1994 Oct; 131(4):359-68. PubMed ID: 7921224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]